Opthea sees final patient for Phase 2b eye disease trial

Company News

by Rachael Jones

Biopharmaceutical company Opthea (ASX:OPT) for eye disease has seen the final patient in the Company’s Phase 2b trial of OPT-302 for wet age-related macular degeneration (AMD) has completed their last clinical visit.

This important milestone paves the way for the company to finalise data cleaning activities.

Patients enrolled in Opthea’s double-masked Phase 2b trial received intravitreal injections of OPT302 on a monthly basis for 6 months.

Of the 366 patients randomised in the trial, 348, that's 95.1 per cent of patients completed the week 24 visit.

Shares in Opthea (ASX:OPT) closed -2.16 per cent lower at $0.68 yesterday.

Rachael Jones

Finance News Network
Rachael comes to FNN after working for Fairfax Media covering international breaking news, including the global economy and politics. She joined FNN in February 2018. She has reported on Australia’s finance news for various organisations since 2000 and has also interviewed a number of key business players, including Bill Gates. Rachael has also worked across a number of countries, including the UK and the US.